Angle Share Discussion Threads

[radderssandy] 08/2/2024 18:15

Thanks Miavoce & Goosed.

[miavoce] 08/2/2024 17:27

Video of the Angle conference presentation which took place today (thanks for flagging the conference goosed).

[boris cobaka] 08/2/2024 16:19

New lower low since the 'spike'.
Not much volume but enough to let it drip lower. "Alamo' stops to be hit soon.

[jibba jabber] 08/2/2024 15:12

Looks like a drifting down back to 10p area

[rb1947] 08/2/2024 09:19

She is a just a bitter ex employee I am sure you must have been a joy to work with NOT

[adw198] 08/2/2024 09:05

Aren’t ET claims in the public domain? If so could someone direct me to the case so I can read what bones699 is so bitter about?

[atmysignal] 08/2/2024 08:53

Think of your husband and children. The ax you are grinding is affecting your family life.When is it time to move on and enjoy life?Look outside your window.It's called life, and it's passing you by.

[bones699] 08/2/2024 08:47

Any day, another dollar, back to watching paint dry at the money pit!

Such a car crash its all there in black and white!

[boris cobaka] 08/2/2024 08:25

Thanks Timbo. Very interesting.

[rb1947] 08/2/2024 07:53

Timbo, thanks for the feedback .

[gooosed] 08/2/2024 07:51

Angle presenting on day two (today) of US online conference.

Thanks for the comprehensive feedback timbo.

[adw198] 08/2/2024 07:44

Thanks for the write up. Hopefully we’ll start seeing a regular announcement of new deals / pilots.

The revenue forecasts are a bit vague from what I can see, but so long as they can get a raise away I wouldn’t be too worried about dilution if they can really show there’s a future market.

[waterloo01] 08/2/2024 07:31

Thanks Timbo.

[bones698] 08/2/2024 00:26

Great report timbo like the details and searching questions . It doesn't look like we will be getting much in the way of big news anytime soon though but does look like when it comes it could be transformative later this year . They are cutting it very fine though

[timbo003] 07/2/2024 23:28

>>>Rb1947, I did put your question concerning Prostate study results to Ian after the meeting, but I got an incomplete reply, I have since asked for clarification, will post it here if and when I get a reply

[timbo003] 07/2/2024 23:10

It was another informative meeting Waterloo, no new news (obviously) but quite a few new insights. The slide deck was more or less the same as that used at Proactive a couple of weeks ago. There were 5 companies presenting and Angle were on last (never a good place to be), we had about 10 minutes for Q&A and I have summarised some of the questions and responses below

I had a quick chat with the CFO before the meeting and asked him (in jest) whether Parsortix might soon gain a "by Royal appointment" accreditation. I speculated that HM's cancer could be bladder cancer and that if it was, Parsortix could be useful tool for tracking any cancer cell mutations. Ian opined that there was no way of knowing who was treating HM and what treatments was being employed, or whether the physicians were advocates of monitoring CTCs and Persortix in particular ☹️




Q&As


Q: Looking at it from a business man’s perspective, I would be interesting in your comments on funding, briefly financial highlights, revenues for half year trebled to £2.2m, on the other hand you went through the thick end of £10m during that period of time and that is not an entirely comfortable position to read as a potential investor.

A: That was planned investment, we raised £20m in June 2022, we are deploying the capital on specific activities, clinical studies, generating data that will get us customers. We are not just spending willy-nilly, this is actual planned expenditure And the medical industry, the nature of it is that You have to generate data to convince people particularly where you are doing a pioneering activity such as ourselves and particularly where people need to be convinced and the way to do that is through data and through partnerships and collaborations that costs money, you run a clinical study it takes a number of years, we have got the only FDA cleared product, that takes a lot of money, most of our competitors cannot do that, so if you want a traditional organisation, we are not a dividend, we are not a safe stock, but we are pioneering we are developing and we are deploying the capital that we raised, now in terms of what that means going forward, we needed to give a trading update back in november, that was revenues for the full year was only £2.2m, yes it is modest at this stage, the money we have got will take us out to Q2 2025, we are aiming to be cash flow break even by end of 2025, so we do have a gap in terms of getting through to cash flow breakeven, we are seeking to fill that with either accelerating revenues further if we can, getting milestone payments or doing deals with large strategics or corporates, but we are doing that on a shoe string compared to our American cousins, but the nature of the industry we are in means we have to deploy capital to get that leadership position, we are the only company with FDA clearance, we’ve got best in class results from the studies in ovarian 95.4% area under the curve all those things cost money, they don’t happen by not spending money.


Q: Can I draw from that if I invested I could expect a rights issue somewhere in early 2025?

A: As I’ve just explained, we are seeking to accelerate revenue growth or we are seeking to get milestone payments from strategic partners which would mean that we don’t have to do a capital raise. Historically we have done a capital raise every year because we were much earlier in the process to commercialisation, so you know, that is part of being a listed company, you know, you can raise capital, we are very tightly focusing our spend, we are a platform technology but we are only working on a limited number of cancers, we don’t need to raise immediately, clearly we will need capital to fill that gap, whether that is from a partner or from the market or see when we get to that point.


Q: You mentioned the NCCN guidelines for secondary biopsies in metastatic breast cancer in the US, what % of patients undergo a secondary biopsy and what % of patients have a CTC biopsy instead?

A: For the current standard of care in the US, the guidelines require a biopsy where it is possible, in reality just under 50% get a biopsy, the remainder are either too sick for the operation or they elect not to have it, they don’t want to go through another operation, or there is not enough material available so if it is a lung biopsy they cannot get enough out, or if it is in the bones, obviously if it is in the brain it is too dangerous and your question was what % of patients have a CTC biopsy? Zero, this is what we are working to try and achieve, a groundswell change in the way medical scientists are operating.

Q: Do you suppose that some of the patients die from the result of the biopsy?

A: Yes some of them do, and also some die from being given drugs which have side effects and no benefit, even more of them die from that.

Q: There has been an incredibly long accumulation of data that should create visibility for the world for companies to see the potential, why is this not stabilising the share price? Please explain to me the correlation?

A: We cannot control the supply and demand in the stock market. There have been massive movements of capital away from growth stocks, pushed down by redemptions from funds for 28 months in a row where people have taken their money out of investment funds, this is not an Angle specific thing, every single med-tech stock pretty much in the world and certainly in the UK is heavily down, but I couldn’t agree with you more, that is why we do these kind of meetings, it is to get more interest, more understanding, When you are trying to do something new, where people don’t know about it and we can sit in an ivory tower and assume they know about it, but they don’t, so we have to go out and spread that message.

Q: Is there an alternative method of funding that mitigates the share price instability.


A: If we go back to the slide I was showing, just one customer Eisai, Eisai currently has 80 clinical trials with 60K patients, a base price $4.6K for a tube of blood, we have discounted that to $2.5K for the pilot, each patient has a minimum of three time points so just this one company 60K patients, three time points at $4.6K each, there is a huge opportunity for building revenue. It took us the best part of a year to close the negotiation with Eisai, including six months waiting for their ???? but now we are in and last week I went to New York and met their people and talked to them about this project and other potential projects and they understand it, they want to see the data from the pilot so we cannot get ahead of ourselves, we have to show them that we have good data, but this is just one company. They are probably 20th on the list of top 20 companies they are not the biggest, there are other big companies and they can all benefit themselves financially and obviously we can too, so my hope is that by working with these kind of companies, they will take us the whole way to the market for a companion diagnostic, so they will pay for us to obtain extended FDA clearance, they will pay for marketing, they will probably be the customer who pays for it. So if you are selling a drug for $100K, would you pay for a blood test for a couple of thousand? Of course you would if you can get $100K for selling the drug, so there are plenty of opportunities for us to just do a companion diagnostic paid for by them.

[waterloo01] 07/2/2024 18:02

How was the event Timbo?

[bones699] 07/2/2024 17:15

How's the watching paint dry business going Bones698 having fun?

[bones698] 07/2/2024 16:50

Matched and more by some chunky sells . Seems to be the pattern ATM . No idea who would sell now after the recent spike though but each to their own

[bones699] 07/2/2024 12:57

Really didn't have much impact on the share price trailing downwards!

[rb1947] 07/2/2024 08:44

Some chunky buys going through this morning

[millwallfan] 06/2/2024 14:22

Tim. Any feedback on key presentation issues and Q&A elements would be very much appreciated together with your personal opinion if the meeting ends with a positive, neutral or negative .

[timbo003] 06/2/2024 13:52

>>Rb

👍